Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...

A once-daily pill for ulcerative colitis has delivered strong results in a clinical trial, easing symptoms even in patients ...

Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ...

Abivax SA ADR (NASDAQ:ABVX) shares climbed 7.7% in premarket trading Monday after the clinical-stage biotechnology company ...

DEAR DR. ROACH: You recently wrote about colitis, aka inflammation of the colon. Could you please explain how to treat and prevent it? -- M.C. ANSWER: “Colitis” does mean inflammation of the colon, ...

You were just diagnosed with ulcerative colitis. Now what? Here, gastroenterologists share the 7 questions to ask your doctor ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

Eli Lilly (NYSE:LLY) announced positive results from a late-stage trial of Omvoh (mirikizumab-mrkz) for patients suffering from moderately to severely active ulcerative colitis. The study demonstrated ...

New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...

Johnson & Johnson (NYSE: JNJ) today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that selectively ...